Logo
x

Search

Subscribe Now

Celltrion Healthcare

Celltrion Healthcare Reports Real-World Results Demonstrated Interchangeability of Rituximab Biosimilar

Celltrion Healthcare Reports Real-World Results Demonstrated Interchangeability of Rituximab Biosimilar

  • April 12, 2023
Celltrion Healthcare’s Vegzelma (biosimilar, bevacizumab) Receives the Health Canada’s Approval for the Treatment of Cancer

Celltrion Healthcare’s Vegzelma (biosimilar, bevacizumab) Receives the Health Canada’s Approval for the Treatment of Cancer

  • January 19, 2023
Celltrion Healthcare’s Vegzelma (biosimilar, bevacizumab) Receives the EC’s Approval for the Treatment of Cancers

Celltrion Healthcare’s Vegzelma (biosimilar, bevacizumab) Receives the EC’s Approval for the Treatment of Cancers

  • August 18, 2022
Celltrion Healthcare Receives CHMP Positive Opinion of CT-P16 (biosimilar, bevacizumab) as 1L Treatment of Non-Squamous Non-Small Cell Lung Cancer

Celltrion Healthcare Receives CHMP Positive Opinion of CT-P16 (biosimilar, bevacizumab) as 1L Treatment of Non-Squamous Non-Small...

  • June 27, 2022
Insights+ Key Biosimilars Events of March 2022

Insights+ Key Biosimilars Events of March 2022

  • April 7, 2022
Celltrion Healthcare to Supply Remsima to the Brazilian Federal Government

Celltrion Healthcare to Supply Remsima to the Brazilian Federal Government

  • March 24, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.